文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

插件&应用

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

高级版

套餐订阅购买积分包

AI 工具

文献检索文档翻译深度研究

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2025

[Progress in the treatment of multiple myeloma with daratumumab].

作者信息

Lu J

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):260-264. doi: 10.3760/cma.j.issn.0253-2727.2021.03.016.

DOI:10.3760/cma.j.issn.0253-2727.2021.03.016

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8081942/

Abstract

摘要

相似文献

[1]

[Progress in the treatment of multiple myeloma with daratumumab].

Zhonghua Xue Ye Xue Za Zhi. 2021-3-14

[2]

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.

J Manag Care Spec Pharm. 2021-12

[3]

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

Lancet Oncol. 2021-11

[4]

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med. 2019-5-30

[5]

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med. 2016-10-6

[6]

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Haematologica. 2010-11-25

[7]

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Blood. 2016-10-6

[8]

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Clin Cancer Res. 2017-10-12

[9]

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.

Oncologist. 2018-1-25

[10]

Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.

CEN Case Rep. 2022-5

本文引用的文献

[1]

Use of daratumumab in high risk multiple myeloma: A meta-analysis.

EJHaem. 2020-7-2

[2]

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.

JAMA Oncol. 2020-11-1

[3]

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Blood. 2020-8-20

[4]

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

Lancet Haematol. 2020-5

[5]

Immunotherapy for Multiple Myeloma.

Cancers (Basel). 2019-12-12

[6]

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Lancet. 2019-12-10

[7]

Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.

Cancers (Basel). 2019-11-19

[8]

Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.

Ann Hematol. 2019-10-16

[9]

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Lancet. 2019-6-3

[10]

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Cancer. 2019-5-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索